BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Deloitte
US Army
Express Scripts
Boehringer Ingelheim
Daiichi Sankyo
Healthtrust
Citi
Medtronic
Chubb

Generated: January 23, 2018

DrugPatentWatch Database Preview

OXYCONTIN Drug Profile

« Back to Dashboard

Which patents cover Oxycontin, and what generic alternatives are available?

Oxycontin is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are twenty patents protecting this drug and seven Paragraph IV challenges.

This drug has five hundred and twenty-six patent family members in forty-seven countries.

The generic ingredient in OXYCONTIN is oxycodone hydrochloride. There are seventeen drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the oxycodone hydrochloride profile page.
Summary for OXYCONTIN
Drug patent expirations by year for OXYCONTIN
Pharmacology for OXYCONTIN
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists

US Patents and Regulatory Information for OXYCONTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-004 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-006 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-002 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-002 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-005 Apr 5, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-006 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-003 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-006 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-003 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-003 Apr 5, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for OXYCONTIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-001 Apr 5, 2010 ➤ Subscribe ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-002 Apr 5, 2010 ➤ Subscribe ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-004 Apr 5, 2010 ➤ Subscribe ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-002 Apr 5, 2010 ➤ Subscribe ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-005 Apr 5, 2010 ➤ Subscribe ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-007 Apr 5, 2010 ➤ Subscribe ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-006 Apr 5, 2010 ➤ Subscribe ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-005 Apr 5, 2010 ➤ Subscribe ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-003 Apr 5, 2010 ➤ Subscribe ➤ Subscribe
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-006 Apr 5, 2010 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for OXYCONTIN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablet 20 mg ➤ Subscribe 10/29/2010
➤ Subscribe Extended-release Tablet 30 mg, 60 mg and 80 mg ➤ Subscribe 10/18/2010
➤ Subscribe Extended-release Tablet 10 mg ➤ Subscribe 10/25/2010
➤ Subscribe Extended-release Tablet 40 mg ➤ Subscribe 10/4/2010
➤ Subscribe Extended-release Tablet 15 mg ➤ Subscribe 10/28/2010
➤ Subscribe Extended-release Tablets 15 mg ➤ Subscribe 2/15/2007
➤ Subscribe Extended-release Tablets 30 mg and 60 mg ➤ Subscribe 1/3/2007

Non-Orange Book US Patents for OXYCONTIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,775,809 Tamper resistant dosage forms ➤ Subscribe
8,834,925 Tamper resistant dosage forms ➤ Subscribe
7,842,307 Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent ➤ Subscribe
8,529,948 Pharmaceutical formulation containing gelling agent ➤ Subscribe
8,192,722 Abuse-proof dosage form ➤ Subscribe
8,999,961 Pharmaceutical formulation containing gelling agent ➤ Subscribe
7,129,248 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone ➤ Subscribe
7,141,250 Pharmaceutical formulation containing bittering agent ➤ Subscribe
8,652,515 Pharmaceutical formulation containing an opioid agonist, opioid antagonist and irritant agent ➤ Subscribe
8,821,929 Tamper resistant dosage forms ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for OXYCONTIN

Supplementary Protection Certificates for OXYCONTIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
292 Luxembourg ➤ Subscribe PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
US Army
AstraZeneca
UBS
Chubb
McKesson
Cerilliant
Merck
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot